HCPCS code J0583 – Bivalirudin injection

Key takeaways

J0583 bills bivalirudin at 1 mg per unit, so report the total milligrams given and round any fraction up to the next whole unit.

J0583 covers Angiomax and therapeutically equivalent bivalirudin, while J0582 is reserved for Endo’s bivalirudin, which CMS lists as not therapeutically equivalent.

Medicaid and many commercial payers require the NDC with qualifier N4, but Medicare Part B does not generally require it on J0583 claims.

Bivalirudin comes in single-dose vials, so each Medicare line carries JW for discarded drug or JZ when none was discarded.

Pabau, our practice management and billing platform, captures the NDC, units, and modifier at documentation, which cuts first-pass claim errors.

HCPCS code J0583: Official descriptor and quick reference

HCPCS code J0583 is the billable Level II code with the official CMS descriptor “Injection, bivalirudin, 1 mg.” It covers Angiomax and therapeutically equivalent generic bivalirudin. Bivalirudin is a direct thrombin inhibitor that the FDA approves as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI). That approval includes patients with, or at risk of, heparin-induced thrombocytopenia (HIT). CMS maintains HCPCS Level II and publishes annual updates plus quarterly updates.

Clinical indications and exclusions for J0583

J0583 covers IV bivalirudin given as an anticoagulant in patients undergoing PCI, the single indication on the current Angiomax label. That indication includes patients with HIT or HIT with thrombosis syndrome (HITTS). Each claim needs a supporting ICD-10-CM diagnosis code to establish medical necessity.

Covered indications:

• Anticoagulation in patients undergoing PCI, as an alternative to heparin
• Patients undergoing PCI who have, or are at risk of, HIT or HITTS

Older Angiomax labels listed unstable angina in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) as a separate use. The current label describes PCI broadly instead. When the team gives unfractionated heparin rather than bivalirudin, that drug bills under J1644, per 1,000 units.

Not covered under J0583:

• Oral anticoagulants or any non-injectable bivalirudin form (none exists commercially)
• Other direct thrombin inhibitors (argatroban bills under J0883 for non-ESRD use or J0884 for ESRD on dialysis, and dabigatran is oral)
• Bivalirudin administered in an inpatient setting under Part A (bundled into the DRG and not separately reportable)
• Any off-label use not documented with a supporting diagnosis

J0583 billing unit: How to calculate and report dosage

The billing unit for HCPCS code J0583 is 1 mg. Report the total milligrams administered, rounded up to the next whole number whenever the dose includes a fraction. Rounding down underreports the drug and creates a units mismatch against the administration record.

Bivalirudin is weight-based (typically a 0.75 mg/kg bolus for PCI), so the milligram dose varies by patient. Pull the total from the pharmacy dispense record or nursing infusion log, then convert it directly to units on the claim line.

J0582 vs J0583: Understanding the bivalirudin code split

J0583 is the standard bivalirudin code, in place since 2018. It covers Angiomax and any bivalirudin product that is therapeutically equivalent to it. J0582 took effect on October 1, 2025, and reads “Injection, bivalirudin (Endo), not therapeutically equivalent to J0583, 1 mg.” Use J0582 only when the vial administered is Endo’s product, and check the NDC on that vial before you submit.

The split follows the product, not the indication. Both codes bill at 1 mg per unit, and the vial the dose came from decides which one goes on the claim. After the code, each claim line comes down to three more checks, shown below.

NDC reporting requirements for HCPCS code J0583

NDC reporting for HCPCS code J0583 is required by Medicaid and many commercial payers. Medicare Part B does not generally require it. Medicaid’s requirement comes from the Deficit Reduction Act of 2005, which states rely on to collect drug rebates.

Key NDC submission rules for medical billing workflows involving injectable drugs:

• Format: 11-digit NDC in 5-4-2 format (e.g., 00264-9804-01). The NDC must match the vial administered, not a reference list.
• Qualifier: N4 prefix on CMS-1500 Box 24 or UB-04 Form Locator 43.
• Unit qualifier: UN (units) or ML (milliliters), depending on the payer. Medicare typically uses UN for injectable drugs billed by unit.
• Source: Pull the NDC from the vial label or pharmacy dispense record, not from a static coding reference. NDCs are specific to the manufacturer and the package.

A correctly formatted NDC line on CMS-1500 Box 24 looks like this: N4 00264980401 UN 250 (qualifier, NDC, unit qualifier, quantity).

Medicare reimbursement for J0583: ASP methodology and fee schedule

Medicare Part B reimburses HCPCS code J0583 under the Average Sales Price (ASP) plus 6% methodology, established under 42 CFR 414.904. CMS publishes updated ASP payment limits quarterly (January, April, July, October). Because rates change four times per year, never hardcode a dollar amount as current. Instead, check the CMS Physician Fee Schedule lookup or the quarterly ASP drug pricing files on the CMS Part B Drug Payment Policy page.

Hospital outpatient settings (POS 22) bill J0583 under the Outpatient Prospective Payment System (OPPS). Bundling status under OPPS can change in the annual OPPS Final Rule. Verify it against that calendar year’s OPPS Addendum B before assuming separate payment. Under the Part A inpatient DRG, bivalirudin is not separately billable. Physician office buy-and-bill (POS 11) follows straight ASP+6% on the CMS-1500.

ICD-10 diagnosis codes commonly paired with J0583

Every J0583 claim needs a supporting ICD-10-CM diagnosis code to establish medical necessity. ICD-10-CM codes update each October 1, so verify codes against the current-year code set before submitting. D75.82 has been a non-billable header since October 1, 2022, so a HIT claim needs one of its five-character codes.

Prior authorization and payer requirements for J0583

Medicare Part B generally does not require prior authorization (PA) for HCPCS code J0583 in approved indications when the clinical record supports the diagnosis. Commercial payers often set their own rules.

• Medicare Part B (POS 22, 11): No PA for approved indications. Medical necessity must be documented in the chart, but no pre-service authorization is required.
• Commercial payers: Often require PA for bivalirudin, especially in elective PCI settings. Payer PA requirements change annually, so verify the current policy with each payer before the procedure.
• HIT cases: Emergency or urgent-setting HIT cases are generally exempt from pre-service PA, but retroactive authorization documentation is still advisable.
• Step therapy: Some commercial plans require documented heparin allergy or HIT diagnosis before authorizing bivalirudin in non-HIT PCI. Include relevant history in the PA request.

PA rules vary by payer and plan year. Never rely on last year’s policy. Contact the payer’s provider line or check its online portal before each encounter that involves commercial insurance.

Documentation requirements to support J0583 claims

Incomplete documentation is a frequent reason claims fail on audit. The medical record must support both the indication and the dose administered.

Auditors reviewing J0583 claims look for:

• Physician order specifying bivalirudin with a weight-based or fixed dose
• Diagnosis supporting anticoagulation (HIT confirmation, ACS documentation, or a procedure note for PCI)
• Drug administration record: Drug name, dose in mg, infusion start and stop time, route, lot number, and NDC
• Nursing notes confirming administration and any adverse events
• Pharmacy dispense record matching the NDC and quantity on the claim
• For HIT cases: Platelet count trend, 4T score or equivalent clinical assessment, and hematology consult if available

A structured superbill captures the NDC, units, and supporting ICD-10 code at documentation. That lowers the chance of a mismatch between the chart and the submitted claim.

Place of service and setting-specific billing for J0583

The billing form, claim type, and bundling risk for HCPCS code J0583 all depend on the care setting. Getting the place of service (POS) code wrong is a common technical denial trigger.

Modifiers used with HCPCS code J0583

Two modifiers apply to J0583 claims: JW and JZ. Both apply to drugs from single-dose containers or single-use packages, and bivalirudin comes in single-dose vials. JW, which reports the discarded amount, has been required since 2017. JZ could be reported from January 1, 2023, and became required on July 1, 2023, for lines with no discarded drug.

Since July 1, 2023, every Medicare J0583 line from a single-dose vial needs JW or JZ. CMS began editing claims for these modifiers on October 1, 2023, so a line missing both is returned.

Common claim denial reasons for J0583 and how to avoid them

Most J0583 denials are preventable. The table below maps frequent denial triggers to their codes and fixes, and our guide to medical billing denial codes explains each code in full. For a broader framework, revenue cycle management at the pre-billing stage catches these issues earliest.

For a deeper look at handling denied claims, see our guide to denial management in healthcare.

How Pabau keeps J0583 claim lines clean

Without a connected system, a billing team rebuilds each bivalirudin line by hand. The NDC comes from the pharmacy system, the milligrams from the infusion log, and the modifier from a nurse’s note.

Pabau records the drug code, NDC, administered quantity, and modifier at the point of documentation. Its claims management software then flags a missing NDC, a unit mismatch, or an absent JW or JZ before the claim leaves the practice.

Your team bills from one record per encounter, so the chart and the claim agree on the first submission.

Reduce J0583 billing errors with Pabau

Pabau captures the drug code, NDC, units, and modifiers at documentation, so your billing team submits every bivalirudin claim from accurate data.

Book a demo

Conclusion

Treat J0583 as the default bivalirudin code and J0582 as the exception you confirm from the vial. That one habit settles the code before units, NDC, or modifiers come into play.

The rest is record-keeping. Bill units from the administration record rather than the vial size. Give each payer the NDC it asks for, and add JW or JZ to every single-dose vial line.

The trade-off is a few extra seconds at documentation against a rework cycle later. Book a demo to see how Pabau carries the code, NDC, and modifier from the chart to a clean bivalirudin claim.

Continue your research

Need a clean-claim checklist for injectable drug codes? Clean claim requirements in medical billing covers the technical elements payers check before processing any drug claim.

Want to understand how clearinghouse edits catch NDC errors? Medical claims clearinghouse explained walks through how electronic validation works before a claim reaches the payer.

Looking for a structured approach to superbill design? Superbill guide explains how to structure documentation that supports both the J-code and the ICD-10 pairing on the same claim.

Billing another injectable that needs NDCs and units? HCPCS code J0694 walks through cefoxitin units, NDC reporting, and the denials that follow common errors.

Want a second worked example of JW and JZ? HCPCS code J9228 shows how wastage modifiers and NDCs apply to Yervoy claims.

Frequently asked questions